Promotional Labeling and Advertising Considerations for Prescription Biological Reference and Biosimilar Products- Questions and Answers; Draft Guidance for Industry; Availability

1 organizations filed 1 public comment on Promotional Labeling and Advertising Considerations for Prescription Biological Reference and Biosimilar Products- Questions and Answers; Draft Guidance for Industry; Availability, at the Food and Drug Administration. The comment window closed 764d ago.

Abstract

Open

Commenters (1)

• Association for Accessible Medicinestrade assoc.

  1 filing · confidence 97%